YKYun Pyo Kang

Yun Pyo Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yun Pyo Kang has a total of 238 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma

    by Sae Bom Lee, Allan Pavy, Nolan Beatty, Justin C. Boucher, Jay K. Mandula, Emiliano Roselli, Darwin C. Chang, Rachel V. Jimenez, Hiroshi Kotani, Kayla Reid, et al.

    Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but many patients with large B cell lymphoma (LBCL) experience primary resistance or relapse. To uncover resistance mechanisms, here we examine pre-infusion tumor biopsies and observe that increased immunoregulatory macrophages correlate with poor clinical responses. In murine models, CAR T cell-produced interferon-gamma (IFN-γ) upregulates inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Proteomic profiling reveals that iNOS-expressing macrophages promote apoptosis and cell cycle arrest while downregulating protein synthesis machinery in CAR T cells. Metabolically, CAR T cells exhibit reduced glycolytic intermediates and altered tricarboxylic acid (TCA) cycle activity. Pharmacological inhibition of iNOS enhances CAR T cell treatment efficacy in vivo. Elevated levels of iNOS+CD14+ monocytes in leukaphereses are associated with non-durable responses to CAR T cells. Targeting iNOS in immunoregulatory macrophages, potentially by modulating CAR T-produced IFN-γ, could improve LBCL outcomes.

  • Open Access

    Inhibiting 15-PGDH restores redox homeostasis and confers neuroprotection in Parkinson's disease

    by Young-Kwang Kim, Yun Jae Cha, Se Eun Park, Hee Kyung Kim, Chaesun Kwon, Geonmo Kim, Yoonah R. Oh, Edwin Vázquez-Rosa, Ujjwal Dahiya, Helen Moinova, et al.


  • Top Cited Papers
    Open Access

    Catabolism of extracellular glutathione supplies cysteine to support tumours

    by Fabio Hecht, Marco Zocchi, Emily T. Tuttle, Nathan P. Ward, Fatemeh Alimohammadi, Amal Afzal Khan, Veronica C. Gomes, Bradley Smith, Jennifer J. Twardowski, Bradley N. Mills, et al.

    Restricting amino acids from tumours is an emerging therapeutic strategy with substantial promise 1 . Although typically considered an intracellular antioxidant with tumour-promoting capabilities 2 , glutathione (GSH), as a tripeptide of cysteine, glutamate and glycine, can be catabolized to release amino acids. The extent to which GSH-derived amino acids are essential to cancers is unclear. Here we show that depletion of intracellular GSH does not alter tumour growth and extracellular GSH is highly abundant in the tumour microenvironment, highlighting the potential importance of GSH outside tumours. Supplementation with GSH rescues cancer cell survival and growth in cystine-deficient conditions, and this rescue depends on the catabolic activity of γ-glutamyltransferases. Finally, pharmacological targeting of the activity of γ-glutamyltransferases prevents the breakdown of circulating GSH, reduces tumour cysteine levels and slows tumour growth. Our findings indicate a non-canonical role for GSH in supporting tumours by acting as a reservoir of amino acids. Depriving tumours of extracellular GSH or inhibiting its breakdown is potentially a therapeutically tractable approach for patients with cancer. Furthermore, these findings change our view of GSH and how amino acids, including cysteine, are supplied to cells.


  • Open Access

    Development of a Quantitative LC-MS/MS-Based Assay for Lycosin-II-Analog 3 and Assessment of Its Stability in Biological Matrices

    by Kyoungmin Do, Seongsoo Lee, Jonggwan Park, Jun Hee Hee Oh, Jieun Lee, Yoo-Seong Jeong, Yun Pyo Kang, Hyun Jin Kim, Yoonkyung Park, Wooin Lee

    Lycosin-II (L-II), a 21-amino acid peptide from Lycosa singoriensis venom, exerts antimicrobial activity via membrane depolarization and permeabilization. Subsequent studies identified the analog L-II-3 as a promising antimicrobial therapeutic. Given the pharmacokinetic limitations, such as metabolic instability, often encountered with peptide-based therapeutics, quantitative characterization of the biological stability and degradation mechanisms of L-II-3 is essential for its in vivo translation. Thus, this study aimed to develop and validate a quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for L-II-3 in biological samples and to investigate its degradation mechanisms. Calibration standards in mouse plasma and whole blood were prepared by direct protein precipitation. The assay achieved acceptable accuracy and precision (<15%) across concentration ranges of 100-1,000 nM in both mouse plasma and whole blood. The stability test indicated that L-II-3 was relatively stable in plasma (88.6 ± 6.2% remaining after 60 min) but rapidly disappeared in whole blood (half-life of 19.7 min). Among the various protease inhibitors tested, EDTA and phenanthroline partially prolonged the half-life of L-II-3 in whole blood. Further assessment using cytosolic and ghost membrane fractions prepared from red blood cells (RBCs) indicated that metal-ion-dependent enzymes in the cytosolic fraction are the primary contributors to L-II-3 degradation, with an additional contribution from RBC membrane binding. L-II-3 degradation was also enhanced by microbial proteases secreted from selected microbial strains. This validated LC-MS/MS assay provides a critical tool for upcoming in vivo pharmacokinetic studies of L-II-3 and its analogs, guiding strategies to enhance in vivo circulation time and therapeutic efficacy.

  • Open Access

    Microglial GM3 accumulation impairs Aβ phagocytic activity and promotes neuroinflammation in Alzheimer's disease

    by Se Eun Park, Yun Jae Cha, Young-Kwang Kim, Hee Kyung Kim, Chaesun Kwon, Yoonah R. Oh, Geonmo Kim, Kristen Gah-Hyeon Kim, Hong-Gyun Lee, Yun Pyo Kang, et al.


  • Top Cited Papers
    Open Access

    Targeting FSP1 triggers ferroptosis in lung cancer

    by Katherine Wu, Alec J. Vaughan, Jozef P. Bossowski, Yuan Hao, Aikaterini Ziogou, Seon Min Kim, Tae Ha Kim, Mari N. Nakamura, Ray Pillai, Mariana Mancini, et al.

    Emerging evidence indicates that cancer cells are susceptible to ferroptosis, a form of cell death that is triggered by uncontrolled lipid peroxidation1,2,3. Despite broad enthusiasm about harnessing ferroptosis as a novel anti-cancer strategy, whether ferroptosis is a barrier to tumorigenesis and can be leveraged therapeutically remains unknown4,5. Here, using genetically engineered mouse models of lung adenocarcinoma, we performed tumour-specific loss-of-function studies of two key ferroptosis suppressors, GPX46,7 and ferroptosis suppressor protein 1 (FSP1)8,9, and observed increased lipid peroxidation and robust suppression of tumorigenesis, suggesting that lung tumours are highly sensitive to ferroptosis. Furthermore, across multiple pre-clinical models, we found that FSP1 was required for ferroptosis protection in vivo, but not in vitro, underscoring a heightened need to buffer lipid peroxidation under physiological conditions. Lipidomic analyses revealed that Fsp1-knockout tumours had an accumulation of lipid peroxides, and inhibition of ferroptosis with genetic, dietary or pharmacological approaches effectively restored the growth of Fsp1-knockout tumours in vivo. Unlike GPX4, expression of FSP1 (also known as AIFM2) was prognostic for disease progression and poorer survival in patients with lung adenocarcinoma, highlighting its potential as a viable therapeutic target. To this end, we demonstrated that pharmacologic inhibition of FSP1 had significant therapeutic benefit in pre-clinical lung cancer models. Our studies highlight the importance of ferroptosis suppression in vivo and pave the way for FSP1 inhibition as a therapeutic strategy for patients with lung cancer.


  • Open Access

    Pantothenate kinase 4 controls lipid synthesis for T-cell proliferation by modulating coenzyme A and glutaminolysis

    by Jeong-Ryul Hwang, Chi Thi Ngoc Nguyen, Gwanghoon Ko, Jung-Ah Kang, Yeongseon Byeon, Seowoo Park, Ryunha Chang, Dawoon Jung, Mi Yeon Jeon, Young Hoon Sung, et al.

    During T-cell-mediated inflammatory responses, T cells are activated upon recognizing specific antigens presented by antigen-presenting cells. This recognition initiates signaling through the TCR and CD28, leading to their activation and subsequent clonal expansion. Within the signaling cascades triggered by TCR and CD28 engagement, the CD28-PI3K pathway serves as a central regulator of metabolic reprogramming in T cells, supporting the biosynthetic needs essential for their effective proliferation. In this study, we found that the regulation of PANK4 plays a role in TCR/CD28-mediated CD4+ T-cell proliferation by regulating de novo lipid synthesis. The CD28 signaling pathway negatively regulates PANK4 through direct binding with PDK1, thereby controlling de novo lipid synthesis for CD4+ T-cell proliferation. Interestingly, we found that Pank4-deficient CD4+ T cells enhance coenzyme A synthesis and glutaminolysis, whereby glutamine contributes carbon for fatty acid synthesis and provides nitrogen for coenzyme A biosynthesis. The regulatory role of PANK4 in CD4+ T-cell proliferation was confirmed in models of experimental colitis and influenza A virus infection, where Pank4-deficient CD4+ T cells exhibited greater expansion than their wild-type counterparts when co-transferred. Our findings suggest that PANK4 regulation of de novo lipid synthesis is crucial for TCR/CD28-induced CD4+ T-cell proliferation and represents a potential target for modulating general CD4+ T-cell responses.


  • Open Access

    Lipidomic Network Analysis Reveals Amyloid-β-Induced Lysosomal Lipid Accumulation in the Cortex and Hippocampus of 5xFAD Mice

    by Yun Jae Cha, Young-Kwang Kim, Yun Ji Lim, Chan Ho Kim, Se Eun Park, Yun Pyo Kang, Min-Kyoo Shin

    The 5xFAD mouse model serves as a valuable experimental system for investigating Alzheimer's disease (AD), specifically amyloid-beta (Aβ)-induced AD pathology. In this study, we explored temporal, regional, and sex-specific alternations in the lipidome within the cortex and hippocampus of 5xFAD mice. Our results revealed that lipid alternations become more pronounced with the progression of Aβ pathology in the cerebral cortex and hippocampus. These lipid changes were also more significant in the female mice, which exhibited more severe Aβ pathology than male mice. Through lipid network analysis, we identified AD-specific lipid coexpression network modules in both brain regions, marked by enriched lysosomal lipids such as BMP and GM3. Notably, this lipid profile was also observed in microglia cells overexpressing the Swedish mutant form of Aβ precursor protein (APPswe). Given the critical role of BMP in lysosomal lipid and membrane degradation, and the observed enhancement of GM3 accumulation under lysosomal inhibition in APPswe-transfected microglial cells, these findings suggest that Aβ-mediated microglial lysosomal dysfunction may contribute to AD progression. Overall, we discovered a previously unrecognized role of Aβ in dysregulating lysosomal lipid metabolism and highlighted the utility of lipidomics and network analysis as complementary approaches for elucidating disease mechanisms.


  • Open Access

    CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma

    by Marco Davila, Sae Bom Lee, Yun Pyo Kang, Justin Boucher, Jay Mandula, Emiliano Roselli, Darwin Chang, Rachel Jimenez, Hiroshi Kotani, Kayla Reid, et al.

    Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we examined patients’ intratumoral immune infiltrates and observed that elevated levels of immunoregulatory macrophages in pre-infusion tumor biopsies are correlated with poor clinical responses. CAR T cell-produced interferon-gamma (IFN-γ) promotes the expression of inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Mechanistically, iNOS-expressing macrophages upregulated the p53 pathway, mediating apoptosis and cell cycle arrest in CAR T cells, while downregulating the MYC pathway involved in ribosome biogenesis and protein synthesis. Furthermore, CAR T cell metabolism is compromised by depletion of glycolytic intermediates and rewiring of the TCA cycle. Pharmacological inhibition of iNOS enhances the CAR T cell treatment efficacy in B cell tumor-bearing mice. Notably, elevated levels of iNOS+CD14+ monocytes were observed in leukaphereses of patients with non-durable response to CAR T cell therapy. These findings suggest that mitigating iNOS in tumor-associated macrophages (TAMs) by blocking IFN-γ secretion from CAR T cells will improve outcomes for LBCL patients.


  • Open Access

    Regulation of Ferroptosis in Cancer and Immune Cells

    by Naeyoon Jang, Il-Kyu Kim, Dawoon Jung, Yeonseok Chung, Yun Pyo Kang

    Jang N, et al. Immune Netw. 2025 Feb;25(1):e6. https://doi.org/10.4110/in.2025.25.e6